Novel gene expressed in prostate cancer
AssigneeAgensys, Inc.
InventorsDaniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
Life of this patent
Estimating the term…
Abstract
A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
Claims40
An isolated 22P4F11 protein having the amino acid sequence as shown in FIG. 1A.
An assay for detecting the presence of a 22P4F11 polynucleotide in a biological sample, comprising
- (a) contacting the sample with a polynucleotide probe which specifically hybridizes to the 22P4F11 cDNA contained within the plasmid as deposited with American Type Culture Collection as Accession No. 98985, the polynucleotide as shown in FIG. 1A, or the complements thereof;
- and
- (b) detecting the presence of a hybridization complex formed by the hybridization of the probe with 22P4F11 polynucleotide in the sample, wherein the presence of the hybridization complex indicates the presence of 22P4F11 polynucleotide within the sample.
An assay for detecting the presence of 22P4F11 mRNA in a biological sample comprising:
- (a) producing cDNA from the sample by reverse transcription using at least one primer;
- (b) amplifying the cDNA so produced using 22P4F11 polynucleotides as sense and antisense primers to amplify 22P4F11 cDNAs therein;
- (c) detecting the presence of the amplified 22P4F11 cDNA, wherein the 22P4F11 polynucleotides used as the sense and antisense probes are capable of amplifying the 22P4F11 cDNA contained within the plasmid as deposited with American Type Culture Collection as Accession No. 98985.
A method of detecting the presence of a cancer expressing 22P4F11 protein which comprises determining the level of 22P4F11 protein expressed by cells in a test tissue sample from an individual and comparing the level so determined to the level of 22P4F11 expressed in a corresponding normal sample, the presence of elevated 22P4F11 protein in the test sample relative to the normal sample providing an indication of the presence of such cancer in the individual.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) obtaining a test sample of tissue from the individual;
- (b) determining the level of 22P4F11 mRNA expressed in the test sample;
- (c) comparing the level so determined to the level of 22P4F11 mRNA expressed in a comparable known normal tissue sample,
- the presence of elevated 22P4F11 mRNA expression in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) obtaining a test sample of tissue from the individual;
- (b) determining the level of 22P4F11 protein expressed in the test sample;
- (c) comparing the level so determined to the level of 22P4F11 protein expressed in a comparable known normal tissue sample,
- the presence of elevated 22P4F11 protein in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
Dependencies are inferred from the claim text.